Abl­ynx grabs a €15M mile­stones pay­ment from Mer­ck KGaA; Eye­Gate surges on Valeant pay­out

→ Bel­gium’s Abl­ynx has teed up one of its Nanobod­ies for os­teoarthri­tis for Mer­ck KGaA. The Ger­man com­pa­ny ac­cept­ed it and will now take it in­to the clin­ic, trig­ger­ing a €15 mil­lion mile­stone pay­ment.

→ JDRF says it will sup­port Vi­a­Cyte’s work on a Type 1 di­a­betes pro­gram.

→ Shares of Eye­Gate Phar­ma­ceu­ti­cals $EYEG jumped on the news that it has grabbed a de­vel­op­ment mile­stone from Valeant for its pact cov­er­ing the Eye­Gate II De­liv­ery Sys­tem and EGP-437 com­bi­na­tion prod­uct for post-op­er­a­tive oc­u­lar in­flam­ma­tion and pain in oc­u­lar surgery pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER